Cargando…

S305: PHASE 2 RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER STUDY OF RECOMBINANT ADAMTS13 IN PATIENTS WITH IMMUNE-MEDIATED THROMBOTIC THROMBOCYTOPENIC PURPURA

Detalles Bibliográficos
Autores principales:	Scully, Marie, Baptista, Jovanna, Bhattacharya, Indranil, Cataland, Spero, Coppo, Paul, Cuccia, Loredana, Dutt, Tina, Susan Huang, Shih-Han, Pascual Izquierdo, Cristina, Eva Mingot-Castellano, María, Parnes, Aric, Pavenski, Katerina, Rajavel, Kavitha, Jarque, Isidro, Wang, Linda T., Fernández Zarzoso, Miguel, Zhu, Andy, Mellgård, Björn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Oral Sessions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428421/ http://dx.doi.org/10.1097/01.HS9.0000968132.86513.06

Ejemplares similares

Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study
por: Knoebl, Paul, et al.
Publicado: (2019)

Novel therapies in thrombotic thrombocytopenic purpura
por: Masias, Camila, et al.
Publicado: (2017)

Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017)

Thrombotic Thrombocytopenic Purpura: Pathophysiology, Diagnosis, and Management
por: Sukumar, Senthil, et al.
Publicado: (2021)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

Clinical relapse of immune‐mediated thrombotic thrombocytopenic purpura following COVID‐19 vaccination
por: Deucher, William, et al.
Publicado: (2022)

Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
por: Thomas, Mari R., et al.
Publicado: (2015)

ADAMTS13 conformation is closed in non-immune acquired thrombotic thrombocytopenic purpura of unidentified pathophysiology
por: Joly, Bérangère S., et al.
Publicado: (2022)

Diagnosis and follow‐up of thrombotic thrombocytopenic purpura with an automated chemiluminescent ADAMTS13 activity immunoassay
por: Beranger, Nicolas, et al.
Publicado: (2020)

Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Vendramin, Chiara, et al.
Publicado: (2018)

SARS-CoV-2 vaccination and immune thrombotic thrombocytopenic purpura
por: Shah, Hridaya, et al.
Publicado: (2022)

ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Bonnez, Quintijn, et al.
Publicado: (2023)

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
por: Graça, Nuno A. G., et al.
Publicado: (2019)

P1602: ACUTE EPISODES IN PATIENTS WITH CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA RECEIVING PROPHYLAXIS: POST HOC ANALYSIS OF A RETROSPECTIVE CHART REVIEW STUDY
por: Coppo, Paul, et al.
Publicado: (2023)

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine
por: Pavenski, Katerina
Publicado: (2021)

Prasugrel and Acquired Thrombotic Thrombocytopenic Purpura Associated with ADAMTS13 Activity Deficiency
por: Lopez, Yanet Parodis, et al.
Publicado: (2016)

Congenital Thrombotic Thrombocytopenic Purpura With a Novel ADAMTS13 Gene Mutation
por: Rashid, Anila, et al.
Publicado: (2020)

Measuring ADAMTS-13 activity to diagnose thrombotic thrombocytopenic purpura: a novel, fast fiber-optic surface plasmon resonance immunoassay
por: Bonnez, Quintijn, et al.
Publicado: (2023)

Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)

ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura
por: Manea, Minola, et al.
Publicado: (2006)

Relapsing thrombotic thrombocytopenic purpura with low ADAMTS13 antigen levels: An indication for splenectomy?
por: Lombardi, Anna Maria, et al.
Publicado: (2019)

Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
por: Palandri, Francesca, et al.
Publicado: (2021)

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura
por: Sakai, Kazuya, et al.
Publicado: (2022)

Long-term management of chronic immune thrombocytopenic purpura in adults
por: Palau, Javier, et al.
Publicado: (2010)

Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura
por: Kangro, Kadri, et al.
Publicado: (2020)

Management of thrombotic thrombocytopenic purpura: current perspectives
por: Blombery, Piers, et al.
Publicado: (2014)

Ribosomal and Immune Transcripts Associate with Relapse in Acquired ADAMTS13-Deficient Thrombotic Thrombocytopenic Purpura
por: Edgar, Contessa E., et al.
Publicado: (2015)

Histone-induced thrombotic thrombocytopenic purpura in adamts13(−/−) zebrafish depends on von Willebrand factor
por: Zheng, Liang, et al.
Publicado: (2020)

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study
por: Scully, Marie, et al.
Publicado: (2022)

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine
por: Coppo, Paul, et al.
Publicado: (2018)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection
por: Fang, Fei, et al.
Publicado: (2022)

Acquired Idiopathic ADAMTS13 Activity Deficient Thrombotic Thrombocytopenic Purpura in a Population from Japan
por: Matsumoto, Masanori, et al.
Publicado: (2012)

Management of Thrombotic Thrombocytopenic Purpura with Autoantibodies to ADAMTS-13 and Concurrent Preeclampsia in Pregnancy: Multidisciplinary Team Approach
por: Patrick, Tiffany, et al.
Publicado: (2012)

Congenital Thrombotic Thrombocytopenic Purpura: Atypical Presentation and New ADAMTS 13 Mutation in a Tunisian Child
por: Borgi, A., et al.
Publicado: (2013)

Positive Response and Increase in ADAMTS13 with Scheduled Rituximab in a Patient with Relapsing Thrombotic Thrombocytopenic Purpura
por: Amer, Bahaa, et al.
Publicado: (2019)

An ADAMTS13 mutation that causes hereditary thrombotic thrombocytopenic purpura: a case report and literature review
por: Li, Pengzhu, et al.
Publicado: (2021)

De Novo Mutation of the ADAMTS13 Gene with Mesenteric Ischemia in an Infant with Congenital Thrombotic Thrombocytopenic Purpura
por: Alharbi, Ibrahim, et al.
Publicado: (2021)

Economic impact of a rapid, on‐demand ADAMTS‐13 activity assay for the diagnosis of thrombotic thrombocytopenic purpura
por: White, Alicia, et al.
Publicado: (2022)

ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications
por: Dainese, Cristina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_dv1cl3ratolm9q80ll4v3k4juc